This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Do patients with prolactinomas using dopamine agonist drugs have autonomic dysfunction?

Do patients with prolactinomas using dopamine agonist drugs have autonomic dysfunction?
Reviewed by Claire Howard

1 December 2022 | Claire Howard | EYE - Neuro-ophthalmology | Prolactinoma, cabergoline, dopamine, dynamic pupillary response, static pupillary response
Share This

This prospective study aimed to determine whether there is autonomic dysfunction in patients with prolactinomas using dopamine agonist (DA) drugs by measuring static and dynamic pupillary responses using an automatic pupillometric device.
Included were 25 eyes from 25 patients who were receiving DA for the treatment of prolactinoma and 25 eyes from 25 healthy individuals. Static and dynamic pupillary responses were measured by automatic quantitative pupillometry. The scotopic pupillary diameter was found to be significantly higher in patients receiving DA medication compared with the control group, while pupil contraction time and pupillary dilatation latency were significantly lower. DA drug use changes static and dynamic pupillary responses, probably by increasing sympathetic tone. In conclusion, authors report that both the static and dynamic parameters in prolactinoma patients who received DAs changed compared with healthy individuals. However, more studies are needed to understand whether these changes are due to the DA used or to the pathophysiology of the disease. The authors conclude that pupillometry can be used as a non-invasive method to provide information about changes in the autonomic nervous system in patients receiving DA drug therapy.

Quantitative evaluation of pupil responses in patients with prolactinomas being treated with dopamine agonists.
Ava S, Hazar L, Karahan M, et al.
NEURO-OPHTHALMOLOGY
2022;46(3):154-8.
Share This
CONTRIBUTOR
Claire Howard

Salford Royal NHS Foundation Trust, Salford, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency